PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
Animals
Antineoplastic Agents
/ chemistry
B7-H1 Antigen
/ chemistry
Breast Neoplasms
/ drug therapy
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immunotherapy
Molecular Targeted Therapy
/ methods
Programmed Cell Death 1 Receptor
/ chemistry
Protein Binding
/ drug effects
Protein Conformation
Signal Transduction
T-Lymphocytes
/ drug effects
Tumor Escape
/ drug effects
Tumor Microenvironment
/ drug effects
Breast cancer
Immune checkpoint
Immunotherapy
PD-1
PD-L1
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
02
10
2019
revised:
03
02
2020
accepted:
14
02
2020
pubmed:
20
2
2020
medline:
10
4
2020
entrez:
20
2
2020
Statut:
ppublish
Résumé
Although both the incidence and the mortality rate of breast cancer is rising, there is no potent and practical option for the treatment of these patients, particularly in advanced stages. One of the most critical challenges for treatment is the presence of complicated and extensive tumor escape mechanisms in the tumor microenvironment. Immune checkpoint molecules are of the main immunosuppressive mechanisms used by cancerous cells to block anti-cancer immune responses. Among these molecules, PD-1 (Programmed cell death) and PD-L1 (programmed cell death-ligand 1) have been considered as worthy therapeutic targets for breast cancer therapy. In this review, we intend to discuss the immunobiology and signaling of the PD-1/PD-L1 axis and highlight its importance as a worthy therapeutic target in breast cancer. We believe that the prognostic value of PD-L1 depends on the breast cancer subtype. Moreover, the combination of PD-1/PD-L1 targeting with immune-stimulating vaccines can be considered as an effective therapeutic strategy in breast cancer.
Identifiants
pubmed: 32070710
pii: S0024-3205(20)30185-5
doi: 10.1016/j.lfs.2020.117437
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
B7-H1 Antigen
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
117437Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest There is no conflict of interest.